IOL Chemicals & Pharmaceuticals has reported a strong first-quarter performance, with standalone net profit rising nearly 90% year-on-year to ₹64.48 crore for the quarter ended June 2026. Revenue from operations climbed 37.1% to ₹756.26 crore, highlighting stronger business momentum compared with the same period last year.
Profit Growth Outpaces Revenue
The company’s earnings growth significantly outpaced its revenue expansion. EBITDA rose 60.7% to ₹111.73 crore, while earnings per share increased to ₹2.20 from ₹1.16 a year earlier.
The results point to an improvement in profitability alongside the sharp increase in sales. The company’s net profit margin also strengthened compared with the year-ago quarter.
Chemicals and Pharmaceuticals Drive Momentum
IOL Chemicals operates across chemicals and pharmaceutical products, giving it exposure to both industrial and healthcare-related markets. Its portfolio includes products such as specialty chemicals, solvents and pharmaceutical ingredients.
The latest results come as India’s chemical and pharmaceutical manufacturers continue to focus on capacity expansion, exports and higher-value products. Stronger demand and improved operating performance can provide companies such as IOL Chemicals with opportunities to strengthen margins and scale their businesses.
What the Results Signal
The June-quarter performance gives IOL Chemicals a stronger start to the financial year. However, sustaining the momentum will depend on demand conditions, input costs, product realisations and the company’s ability to maintain operating efficiency.
With revenue expanding strongly and profit growing at an even faster pace, the latest quarter indicates that IOL Chemicals is gaining momentum across its business, positioning the company for a closely watched FY27.
